Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

21. Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. (Abstract)

Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. Patients with heart failure (HF) discharged from the hospital are at high risk for death and rehospitalization. Transitional care service interventions attempt to mitigate these risks.To assess the cost-effectiveness of 3 types of postdischarge HF transitional care services and standard care.Decision analytic microsimulation model.Randomized controlled trials, clinical registries, cohort studies, Centers

2020 Annals of Internal Medicine

22. CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction (Abstract)

CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction The optimal diuretic treatment strategy for patients with acute heart failure and renal dysfunction remains unclear. Plasma carbohydrate antigen 125 (CA125) is a surrogate of fluid overload and a potentially valuable tool for guiding decongestion therapy. The aim of this study was to determine if a CA125-guided diuretic strategy is superior to usual care in terms of short-term renal (...) function in patients with acute heart failure and renal dysfunction at presentation.This multicenter, open-label study randomized 160 patients with acute heart failure and renal dysfunction into 2 groups (1:1). Loop diuretics doses were established according to CA125 levels in the CA125-guided group (n = 79) and in clinical evaluation in the usual-care group (n = 81). Changes in estimated glomerular filtration rate (eGFR) at 72 and 24 hours were the co-primary endpoints, respectively.The mean age

2020 EvidenceUpdates

23. Heart Failure - Systolic Dysfunction

or wall thickness. Gated SPECT may have better inter-observer reliability than echocardiography in assessing ejection fraction. However, the cost and radiation exposure support echocardiography as an appropriate initial evaluation. Functional testing. Exercise stress testing may have a role in the evaluation of some patients with heart failure. Exercise stress testing is useful in evaluating active and significant concomitant coronary artery disease and in assessing functional capacity (...) (dobutamine or dopamine) or phosphodiesterase inhibitors (milrinone) may have a role in the treatment of patients hospitalized for acutely decompensated heart failure who do not respond adequately or in a timely manner to diuretic therapy. Inotropic agents may increase cardiac output and decrease systemic and pulmonary vascular resistance. Although these therapies may improve symptoms and decrease hospitalizations, they are associated with increased mortality. Intermittent bolus or continuous home

2020 University of Michigan Health System

24. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure (Abstract)

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>40%). Sacubitril/valsartan has been compared with a renin-angiotensin-aldosterone-system inhibitor alone in 2 similarly designed clinical trials of patients with reduced and preserved LVEF, permitting examination of its effects (...) across the full spectrum of LVEF.We combined data from PARADIGM-HF (LVEF eligibility≤40%; n=8399) and PARAGON-HF (LVEF eligibility≥45%; n=4796) in a prespecified pooled analysis. We divided randomized patients into LVEF categories: ≤22.5% (n=1269), >22.5% to 32.5% (n=3987), >32.5% to 42.5% (n=3143), > 42.5% to 52.5% (n=1427), > 52.5% to 62.5% (n=2166), and >62.5% (n=1202). We assessed time to first cardiovascular death and HF hospitalization, its components, and total heart failure hospitlizations

2020 EvidenceUpdates

25. Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF (Abstract)

older and had more obesity, less coronary disease, and lower estimated glomerular filtration rate and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels than men. For the primary outcome, the rate ratio for sacubitril-valsartan versus valsartan was 0.73 (95% CI, 0.59-0.90) in women and 1.03 (95% CI, 0.84-1.25) in men (P interaction = 0.017). The benefit from sacubitril-valsartan was attributable to reduction in heart failure hospitalization. The improvement in New York Heart Association (...) Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF Unlike heart failure with reduced ejection fraction, there is no approved treatment for heart failure with preserved ejection fraction, the predominant phenotype in women. Therefore, there is a greater heart failure therapeutic deficit in women compared with men.In a prespecified subgroup analysis, we examined outcomes according to sex

2020 EvidenceUpdates

26. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial Full Text available with Trip Pro

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions , 141 (2), 90-99 2020 Jan 14 Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial

2020 EvidenceUpdates

27. Heart failure with preserved ejection fraction: are angiotensin receptor-neprilysin inhibitors the answer?

been promising results that sacubitril/valsartan may also benefit patients with HFpEF. In the 2012 phase 2 PARAMOUNT trial comparing sacubitril/valsartan to valsartan in patients with an LVEF > 45% and a documented history of heart failure, ARNI therapy was shown to have beneficial effects on surrogate endpoints: biomarkers indicative of heart failure progression as well as echocardiographic evidence of cardiac remodeling. At 12 weeks of follow-up, ARNI therapy was associated with a significantly (...) populations who may demonstrate true benefit from the drug. Commentary by Dr. Adam Skolnick The main challenge in studying heart failure with preserved ejection fraction (HFpEF) is that there are at least four associated phenotypes: aging, obesity, pulmonary hypertension, and coronary artery disease. 16 Combining all phenotypes into one study runs the risk of missing a subtype of HFpEF for which there is benefit or harm. Future studies should attempt to study each phenotype of HFpEF separately in order

2020 Clinical Correlations

28. Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Full Text available with Trip Pro

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library of Medicine (...) Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Am Coll Cardiol Actions , 74 (23), 2893-2904 2019 Dec 10 Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom; Centre of Cardiovascular Research and Education

2020 EvidenceUpdates

29. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial

Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed (...) to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Circulation Actions , 140 (23), 1881-1891 2019 Dec 3 Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation

2020 EvidenceUpdates

30. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease

Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily (...) : Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Am J Cardiol Actions 2019 Nov 19 [Online ahead of print] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease , , , , , Affiliations Expand Affiliations 1 Department of Medicine, Warren Alpert School of Brown University

2020 EvidenceUpdates

31. End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV

End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV | JACC: Heart Failure Advertisement User menu Source Search for this keyword Search Source Search for this keyword Search JACC: Heart Failure DOI: 10.1016/j.jchf.2020.04.001 Letter to the Editor Just Accepted End-stage Heart Failure with COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV Nianguo Dong , Jie Cai (...) , Ying Zhou , Junwei Liu and Fei Li Author + information DOI: Published By: Print ISSN: Online ISSN: Copyright & Usage: © 2020 Author Information This is a PDF-only article. The first page of the of this article appears above. Toolbox Thank you for your interest in spreading the word about JACC: Heart Failure NOTE: We request your email address only as a reference for the recipient. We do not save email addresses. Your Email * Your Name * Send To * Enter multiple addresses on separate lines

2020 American College of Cardiology

32. Heart failure - chronic: Scenario: Information and advice, follow-up, and referral

cardioverter defibrillator (ICD). Coronary revascularization. Cardiac transplantation. [ ; ; ; ; ] Basis for recommendation Indications for referral to a specialist heart failure team The recommendations for referral of people with severe heart failure, heart failure which does not respond to treatment in primary care or the home setting is based on information in the National Institute for Health and Clinical Excellence (NICE) guideline Chronic heart failure in adults: diagnosis and management (...) on physical activity The recommendation on regular low-intensity physical activity in people with stable heart failure is based on the SIGN guideline [ ]. The recommendation to avoid exercise in water in people with NYHA class III and IV heart failure is because immersion in water creates enhanced preload which has been associated with abnormal cardiac responses [ ]. Advice on nutritional status The recommendation to advise people to eat healthily and to maintain a healthy weight is based on information

2020 NICE Clinical Knowledge Summaries

33. Heart failure - chronic: Scenario: End-stage heart failure

Heart failure - chronic: Scenario: End-stage heart failure Scenario: End-stage heart failure | Management | Heart failure - chronic | CKS | NICE Search CKS… Menu Scenario: End-stage heart failure Heart failure - chronic: Scenario: End-stage heart failure Last revised in January 2017 Scenario: End-stage heart failure From age 16 years onwards. When should I suspect end-stage heart failure? People can be regarded as being in end-stage heart failure if they are at high risk of dying within (...) the next 6–12 months. Common symptoms in end-stage heart failure include: Pain. Breathlessness. Persistent cough. Fatigue. Limitation of physical activity. Depression and anxiety. Constipation. Loss of appetite and nausea. Oedema. Insomnia. Cognitive impairment. Predicting the illness trajectory can be difficult. Indicators of people likely to have end-stage heart failure include: Frequent hospital admissions. Poor response to treatment and severe breathlessness at rest (New York Heart Association

2020 NICE Clinical Knowledge Summaries

34. Heart failure - chronic: Scenario: Confirmed heart failure with reduced ejection fraction

on . Consider if an antiplatelet drug is indicated. Consider prescribing an antiplatelet to people with atherosclerotic arterial disease (including coronary heart disease). For further information, see the CKS topics on and . Consider if statin therapy is indicated. For further information, see the CKS topics on and . Ensure that any , comorbidities and precipitating factors are optimally managed. For further information, see the CKS topics on , , , , , , and . People with heart failure due to valve disease (...) remain symptomatic despite optimal treatment with a diuretic, an ACE-inhibitor (or AIIRA), and a beta-blocker should be referred for specialist assessment and management is based on information in the NICE guideline Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care [ ]. Prescribing an antiplatelet drug The recommendation to prescribe an antiplatelet drug for people with heart failure and atherosclerotic arterial disease (including coronary

2020 NICE Clinical Knowledge Summaries

35. Heart failure - chronic: Scenario: Confirmed heart failure with preserved ejection fraction

disease (including coronary heart disease). For further information, see the CKS topics on , and . Consider if statin therapy is indicated . For further information, see the CKS topic on and . Ensure that any causes, comorbidities, and precipitating factors are optimally managed. For further information, see the CKS topics on , , , , , , and . People with heart failure due to valve disease should be referred for specialist assessment and advice regarding follow-up. Screen for depression and anxiety (...) to prescribe an antiplatelet drug for people with heart failure and atherosclerotic arterial disease (including coronary heart disease) is based on information in the NICE guideline [ ]. Prescribing a statin There is considerable evidence of the value of statin treatment in atherosclerotic disease. Two large placebo-controlled trials (n = 5011 and n = 4574) comparing statin treatment with placebo in people with chronic heart failure did not demonstrate a significant reduction in cardiovascular death

2020 NICE Clinical Knowledge Summaries

36. Heart failure - chronic: Managing diuretics

Heart failure - chronic: Managing diuretics Managing diuretics | Prescribing information | Heart failure - chronic | CKS | NICE Search CKS… Menu Managing diuretics Heart failure - chronic: Managing diuretics Last revised in January 2017 Managing diuretics Choice of diuretic Loop diuretics are preferred for the management of oedema due to heart failure. The loop diuretics available in the UK are furosemide (most widely used), bumetanide, and torasemide. [ ; ] Key drug interactions with loop (...) be exacerbated by hypokalaemia of loop diuretics. Advise the person to be aware of (and report) symptoms of lithium toxicity. Monitor lithium levels carefully and adjust the dosage where necessary. For more information, see the CKS topic on . Muscle relaxants — enhanced hypotensive effect with baclofen or tizanidine. Increased effect of curare-like muscle relaxants. Nitrates — enhanced hypotensive effect. Nonsteroidal anti-inflammatory drugs (NSAIDs) — can exacerbate heart failure and increase the risk

2020 NICE Clinical Knowledge Summaries

37. Heart failure - chronic: Managing angiotensin-converting enzyme inhibitors

Heart failure - chronic: Managing angiotensin-converting enzyme inhibitors Managing ACE-inhibitors | Prescribing information | Heart failure - chronic | CKS | NICE Search CKS… Menu Managing ACE-inhibitors Heart failure - chronic: Managing angiotensin-converting enzyme inhibitors Last revised in January 2017 Managing angiotensin-converting enzyme inhibitors Key drug interactions with ACE-inhibitors Important drug interactions of angiotensin-converting enzyme (ACE) inhibitors include: Alcohol (...) be required if clincially appropriate, when there are concerns regarding the person's clinical condition, concomitant drugs, or comorbidities. Advise the person that if they develop diarrhoea and vomiting while taking an ACE-inhibitor, they should maintain their fluid intake and stop the ACE-inhibitor for 1–2 days until they recover. Stopping treatment for a short time is thought to avoid dehydration, hypotension and acute renal failure, and should not cause a sudden deterioration in heart failure

2020 NICE Clinical Knowledge Summaries

38. Heart failure - chronic: COVID-19

Heart failure - chronic: COVID-19 COVID-19 | Prescribing information | Heart failure - chronic | CKS | NICE Search CKS… Menu COVID-19 Heart failure - chronic: COVID-19 Last revised in January 2017 COVID-19 ACEIs and ARBs People who are taking angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) medications (also known as AIIRAs) for any indication should not stop taking these drugs during the COVID-19 pandemic, whether they are unaffected by the virus or have

2020 NICE Clinical Knowledge Summaries

39. Heart failure - chronic: Beta-blockers

Heart failure - chronic: Beta-blockers Managing beta-blockers | Prescribing information | Heart failure - chronic | CKS | NICE Search CKS… Menu Managing beta-blockers Heart failure - chronic: Beta-blockers Last revised in January 2017 Beta-blockers Contraindications and cautions of beta-blockers Do not prescribe beta-blockers to people with: A history of asthma or bronchospasm. Reversible or severe chronic obstructive pulmonary disease (COPD). Beta-blockers can be used in people with COPD (...) without significant reversible airways obstruction. Known intolerance or hypersensitivity to beta-blockers. Severe or symptomatic bradycardia (heart rate less than 60 beats per minute). Sinoatrial block, second- or third-degree heart block (unless there is a pacemaker in place). Severe or uncontrolled heart failure. Severe or symptomatic hypotension (systolic blood pressure less than 90 mmHg). Severe peripheral arterial disease (including intermittent claudication) or Raynaud's syndrome. Sick sinus

2020 NICE Clinical Knowledge Summaries

40. Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure. Decision Support Document 119.

with advanced heart failure. Decision Support Document 119. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 839kB Abstract Patients with moderately severe or severe heart failure often experience cardiac decompensation, which manifests itself in an increase of pulmonary arterial pressure long before the classic symptoms (shortness of breath, water retention, etc.) arise. As a result, hospitalisation and a deterioration in quality of life occur repeatedly. The systematic (...) Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure. Decision Support Document 119. Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure - Repository of AIHTA GmbH English | Browse - - - Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure Winkler, R. and Wild, C. (2020): Implantation of a wireless pulmonary artery pressure sensor in patients

2020 Austrian Institute of Health Technology Assessment